Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for treating an acute myeloid leukemia

a myeloid leukemia and acute treatment technology, applied in the field of acute treatment of acute myeloid leukemia, can solve the problems of a large disease recurrence, poor prognosis of patients harboring calm-af10 fusion, and the ineffective treatment of patients with calm-af10 fusion by standard chemotherapeutic strategies

Pending Publication Date: 2022-03-31
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a compound called Compound 1, which is a small molecule that can treat acute myeloid leukemia (AML). The patent describes methods for using Compound 1 alone or in combination with other chemotherapy agents to treat AML. The technical effect of this patent is to provide a new treatment option for AML that targets a specific molecule, leading to improved outcomes for patients with this disease.

Problems solved by technology

Disease recurrence is a major problem in the treatment of AML.
Standard chemotherapeutic strategies are often not very effective in treating patients with CALM-AF10 fusions.
Those patients harboring the CALM-AF10 fusion have a particularly poor prognosis with no currently available clinical-grade, targeted therapeutics for this disease subtype.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating an acute myeloid leukemia
  • Method for treating an acute myeloid leukemia
  • Method for treating an acute myeloid leukemia

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0230]Immunodeficient mice (NRG-SGM3) were injected with the P31-Fujioka cell line. Ten days after injection, engraftment of P31 cells in mice was confirmed by flow-cytometric assessment of the human CD45 marker (data not shown). One cohort of mice was orally administered Compound 1 and an age and engraftment matched hohort was administered vehicle control. The results are illustrated in FIG. 1, which shows a survival curves for the Compound 1 vs vehicle treated animals (n=5 mice per group, *P<0.002). The results indicate that treatment with Compound 1 significantly delayed the latency of disease in mice compared to the control.

example 2

[0231]The following study was conducted in a mouse model of acute myeloid leukemia (AML) based on intravenous (IV) injection of human MOLT-4-AML cells into male non-obese diabetic (NOD) severe combined immunodeficiency (SID) mice. MOLT-4 cells are CD3 positive. The NOD-SCID mice were obtained from Jackson Laboratory, Bar Harbor Me.

[0232]Male NOD-SCID mice were inoculated with MOLM13 human AML tumor cells from ATCC (5×106 cells in 200 μL PBS) by intravenous (IV) injection of 0.2 ml / mouse. Three days after tumor inoculation, mice were randomized into four groups of five mice per group, and each group was dosed as follows once each day: (Group 1) orally administered vehicle (0.5% HPMC), (Group 2) orally administered 12.5 mg / kg of Compound 1 in HPMC, (Group 3) orally administered 10 mg / kg of Compound 2 in HPMC, and (Group 4) orally administered a combination of 12.5 mg / kg of Compound 1 and 10 mg / kg of Compound 2 in HPMC for up to 75 days.

[0233]Results of the study are shown in FIGS. 2-5...

example 3

[0234]Male NOD-SCID mice were inoculated with MOLT human acute lymphoblastic leukemia (ALL) tumor cells from ATCC (1×107 cells in 200 μL PBS) by intravenous (IV) injection of 0.2 ml / mouse. Seven days after tumor inoculation, mice were randomized into seven groups of five mice per group, and each group was dosed as follows: (Group 1) orally administered vehicle of 0.5% HPMC and 0.1% Tween 80 daily, (Group 2) orally administered 10 mg / kg Compound 1 twice per week, (Group 3) orally administered 10 mg / kg Compound 2 daily, (Group 4) administered 1 mg / kg doxorubicin by intraperitoneal (IP) injection once per week, (Group 5) administered 0.5 mg / kg doxorubicin by IP injection once per week, (Group 6) administered 50 mg / kg Ara-C twice per week by IP injection, and (Group 7) administered 70 mg / kg Ara-C by IP injection once per week.

[0235]The resulting survival curves of the seven groups of mice from that study are shown in FIG. 6. As shown in FIG. 6, the maximum number of days of survival of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An aspect described herein includes a method for treating acute myeloid leukemia (AML) in a subject in need thereof comprising, administering to the subject an effective amount of a small molecule tubulin polymerization inhibitor compound. More particularly, another aspect described herein includes a method for treating acute myeloid leukemia in a subject in need thereof comprising, administering to the subject an effective amount of the small molecule tubulin polymerization inhibitor compound described herein in combination with a chemotherapeutic agent.

Description

INTRODUCTION[0001]Described herein is a method for treating an acute myeloid leukemia (AML) in a subject in need thereof comprising, administering to the subject an effective amount of a small molecule tubulin polymerization inhibitor compound. More particularly described herein is a method for treating an AML in a subject in need thereof comprising, administering to the subject an effective amount of a small molecule tubulin polymerization inhibitor compound alone or in combination with a chemotherapeutic agent.BACKGROUND[0002]Disease recurrence is a major problem in the treatment of AML. Elderly patients with p53 mutant mediated AML are at an extremely high risk of relapse, particularly those having complex karyotype (60-80%) and therapy-related AML (30%) in whom mutations of the tumor suppressor p53 occur frequently (Nishida Y, et al.,; The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/506A61K31/437A61P35/02
CPCA61K31/506A61P35/02A61K31/437A61K31/4184A61K31/407A61K45/06A61K2300/00
Inventor WEETALL, MARLA L.DESHPANDE, ANIRUDDHA JAYANTBARBOSA GUERRA, KARINA OFELIA
Owner SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com